BBC News

Blood cancer therapy reverses incurable leukaemia in some patients

NEJM

Nejmoa2505478

Metaculus

Stirling News

Innovative therapy gives hope to patients whose blood cancer seemed incurable

Medicalxpress

2025 12 Ready Cell Gene Therapy Tackles.Html

The Standard

News Medical

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

Sky News

Patients with previously untreatable blood cancer now disease-free after world-first gene therapy

Independent

At 13, I thought my leukaemia was incurable. But a new treatment has made me cancer-free

Pioneering new treatment reverses incurable blood cancer in some patients

The Times of India

World-first gene therapy reverses 'incurable' leukemia in some patients

Blood Journals Portfolio

Universal Base Edited Car7 T Cells For T Cell

A clinical trial involving nine children and two adults with T-cell acute lymphoblastic leukaemia at Great Ormond Street Hospital and King's College Hospital showed that 82% of patients achieved deep remission after receiving BE-CAR7 treatment, enabling them to proceed to stem cell transplant without detectable disease.

A clinical trial involving nine children and two adults with T-cell acute lymphoblastic leukaemia at Great Ormond Street Hospital and King's College Hospital showed that 82% of patients achieved deep remission after receiving BE-CAR7 treatment, enabling them to proceed to stem cell transplant without detectable disease.

The BE-CAR7 therapy uses base editing technology to modify healthy donor T-cells through three key DNA changes: disabling existing receptors to make them universal, removing the CD7 marker to prevent self-destruction, and adding a chimeric antigen receptor to target cancerous T-cells.

The BE-CAR7 therapy uses base editing technology to modify healthy donor T-cells through three key DNA changes: disabling existing receptors to make them universal, removing the CD7 marker to prevent self-destruction, and adding a chimeric antigen receptor to target cancerous T-cells.

Alyssa Tapley from Leicester, who was 13 when she became the first patient to receive the base-edited treatment in 2022, is now 16 and disease-free, with plans to pursue an apprenticeship in biomedical science and eventually work in blood cancer research.

Alyssa Tapley from Leicester, who was 13 when she became the first patient to receive the base-edited treatment in 2022, is now 16 and disease-free, with plans to pursue an apprenticeship in biomedical science and eventually work in blood cancer research.

The treatment showed that 64% of patients remain disease-free, with some patients now three years post-treatment and off medication, though side effects including low blood counts, cytokine release syndrome and rashes were reported as manageable by researchers.

The treatment showed that 64% of patients remain disease-free, with some patients now three years post-treatment and off medication, though side effects including low blood counts, cytokine release syndrome and rashes were reported as manageable by researchers.

Base editing is an advanced form of CRISPR technology that changes single letters of DNA code without cutting the DNA strand, reducing the risk of chromosomal damage while allowing scientists to precisely modify the genetic instructions within living cells.

Scitechdaily

Base editing is an advanced form of CRISPR technology that changes single letters of DNA code without cutting the DNA strand, reducing the risk of chromosomal damage while allowing scientists to precisely modify the genetic instructions within living cells.

Great Ormond Street Hospital Charity has committed over 2 million pounds to support treatment for an additional 10 patients as part of an extended cohort, with the trial sponsored by GOSH and supported by the Medical Research Council, Wellcome and the National Institute for Health and Care Research.

Great Ormond Street Hospital Charity has committed over 2 million pounds to support treatment for an additional 10 patients as part of an extended cohort, with the trial sponsored by GOSH and supported by the Medical Research Council, Wellcome and the National Institute for Health and Care Research.

BBC News #

NEJM #

Metaculus #

Stirling News #

Medicalxpress #

The Standard #

News Medical #

Sky News #

Independent #

AOL #

The Times of India #

MSN #

Blood Journals Portfolio #

The treatment showed that 64% of patients remained disease-free for periods ranging from three months to three years after treatment, with side effects including low blood counts, cytokine release syndrome and rashes being manageable according to researchers.

The treatment showed that 64% of patients remained disease-free for periods ranging from three months to three years after treatment, with side effects including low blood counts, cytokine release syndrome and rashes being manageable according to researchers.

Great Ormond Street Hospital Charity has committed over 2 million pounds to support treatment for another 10 patients as part of an extended cohort, following the initial trial results published in the New England Journal of Medicine and presented at the American Society of Hematology Annual Meeting.

Great Ormond Street Hospital Charity has committed over 2 million pounds to support treatment for another 10 patients as part of an extended cohort, following the initial trial results published in the New England Journal of Medicine and presented at the American Society of Hematology Annual Meeting.

Gene-Edited Therapy Achieves 82% Remission in Leukaemia Trial

Gene-Edited Therapy Achieves 82% Remission in Leukaemia Trial

Articles on this story

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Gene-Edited Therapy Achieves 82% Remission in Leukaemia Trial

Gene-Edited Therapy Achieves 82% Remission in Leukaemia Trial

Articles on this story

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters